||Paroxetine hydrochloride is a serotonin uptake inhibitor that is effective in the treatment of depression.
||CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, 5 and 1, respectively.
||GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effecti
||CMPD101 is a membrane-permeable inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM) used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and P
||GRKs-IN-1 hydrochloride is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine. GRKs-IN-1 hydrochloride, Compound 1
||GRKs-IN-1 is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine. GRKs-IN-1, Compound 14as, has remarkable potency